251 related articles for article (PubMed ID: 11429322)
1. MICA and MICB genes: can the enigma of their polymorphism be resolved?
Stephens HA
Trends Immunol; 2001 Jul; 22(7):378-85. PubMed ID: 11429322
[TBL] [Abstract][Full Text] [Related]
2. Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.
Cox ST; Madrigal JA; Saudemont A
Tissue Antigens; 2014 Sep; 84(3):293-303. PubMed ID: 24962621
[TBL] [Abstract][Full Text] [Related]
3. Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behcet's disease in Caucasian patients.
Hughes EH; Collins RW; Kondeatis E; Wallace GR; Graham EM; Vaughan RW; Stanford MR
Tissue Antigens; 2005 Sep; 66(3):195-9. PubMed ID: 16101830
[TBL] [Abstract][Full Text] [Related]
4. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T
Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531
[TBL] [Abstract][Full Text] [Related]
5. Associations of MICB with cervical cancer in north-eastern Thais: identification of major histocompatibility complex class I chain-related gene B motifs influencing natural killer cell activation.
Jumnainsong A; Jearanaikoon P; Khahmahpahte S; Wongsena W; Romphruk AV; Chumworathayi B; Vaeteewoottacharn K; Ponglikitmongkol M; Romphruk A; Leelayuwat C
Clin Exp Immunol; 2008 Aug; 153(2):205-13. PubMed ID: 18505429
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells.
Borrego F; Kabat J; Kim DK; Lieto L; Maasho K; Peña J; Solana R; Coligan JE
Mol Immunol; 2002 Feb; 38(9):637-60. PubMed ID: 11858820
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.
Thomas M; Boname JM; Field S; Nejentsev S; Salio M; Cerundolo V; Wills M; Lehner PJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1656-61. PubMed ID: 18230726
[TBL] [Abstract][Full Text] [Related]
9. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1.
Rodríguez-Rodero S; González S; Rodrigo L; Fernández-Morera JL; Martínez-Borra J; López-Vázquez A; López-Larrea C
Eur J Immunol; 2007 Jul; 37(7):1938-53. PubMed ID: 17557375
[TBL] [Abstract][Full Text] [Related]
11. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
13. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
Front Immunol; 2018; 9():926. PubMed ID: 29765374
[TBL] [Abstract][Full Text] [Related]
14. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences.
McCann FE; Eissmann P; Onfelt B; Leung R; Davis DM
J Immunol; 2007 Mar; 178(6):3418-26. PubMed ID: 17339436
[TBL] [Abstract][Full Text] [Related]
15. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
[TBL] [Abstract][Full Text] [Related]
17. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
19. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
